VU0364770
CAY-22927-5 5 mg
Data Sheet: 
SDS:
SDS:
CAS
61350-00-3
Formulation
A crystalline solid
Purity
≥98%
MW
232,7
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A positive allosteric modulator of metabotropic glutamate receptor 4 (mGluR4; EC50 = 1.1 µM in a calcium mobilization assay); a positive allosteric modulator of mGluR6 (EC50 = 6.8 µM) and an antagonist of mGluR5 (IC50 = 17.9 µM); binds to monoamine oxidase A (MAO-A) and MAO-B (Kis = 8.5 and 7.2 µM, respectively), as well as the human norepinephrine transporter in a panel of 68 receptors, ion channels, and transporters at 10 µM; decreases haloperidol-induced catalepsy and reduces increases in the number of premature reactions in response to a light cue, indicating improved attentional control, in a 6-OHDA rat model of Parkinson’s disease at 56.6 mg/kg
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
